Many substances in the environment have a potentially destructive effect on white blood cells, the main agents of the immune defenses.1
As a biochemist, Dr. Mirko Beljanski knew that any cell, in order to duplicate, needs special and specific “primers” to catalyze the process of cell duplication. Besides this initial step of cell division, there is no other intervention by these RNA-fragments. All organisms proceed this way.2, 3
Dr. Beljanski prepared short fragments of RNA primers from Escherichia coli K-12 (a strain recognized as totally innocuous)4 according to the model of what the healthy body provides for cell multiplication in a selective and specific manner.5
These RNA fragments do not interfere with other cells. They simply support the body’s immune system to help boost the cells, which naturally enhance the generation of white blood cells and platelets.6,7*
Contents: 10 units per bottle. Each serving of ReaLBuild® contains 20 mg ribonucleic extract of Escherichia coli K-12.
Suggested Daily Intake as a Dietary Supplement: Take 4 to 6 capsules per day with a glass of water or as recommended by your healthcare practitioner. Do not exceed the recommended daily dosage.
Best Conservation Method: Keep the bottle in a dry and cool environment. Do not freeze. Close the lid after use.
Caution: The use of ReaLBuild® is not recommended for people following a treatment with Benzodiazepine or when an aplasia is sought in the case of certain cancer treatments. Regular intake of magnesium is recommended.
From our laboratories to your hands, quality control standards are continuously applied to assure you a product worthy of the Beljanski® name and reputation.
1D. BRAUN, J.E. HARRIS, “Modulation of the Immune Response by Chemotherapy.” Pharmacol Ther. 14, 89-122 (1981).
2G.K. KRIMBLE, “Essential and Conditionally-Essential Nutrients in Clinical Nutrition.” Nutrition Research Reviews, (1993) 6, 97-119.
3W.C. FANSLOW, A.D. KULKARNI, C.T. VAN BUREN, F.G. RUDOLPH, “Effect of Nucleotide Restriction and Supplementation on Resistance to Experimental Murine Candidiasis.” Journal of Parenteral and Enteral Nutrition, Vol. 12, No 1, (1998) pp 49-52.
4http://epa.gov/biotech_rule/pubs/fra/fra004.htm. Escherichia coli K-12 Derivatives Final Risk Assessment.
5M. BELJANSKI, “The Regulation of DNA Replication and Transcription.” 3rd ed. demosMEDICAL, New York, NY, 2013, pp. 11-15.
6M. BELJANSKI, M. PLAWECKI, P. BOURGAREL, M. S. BELJANSKI, “Nouvelles substances (R.L.B.) actives dans la leucopoïese et la formation des plaquettes.” Bull. Acad. Nat. Med., 1978, 162, Volume no 6, pp. 475-781.
7M. BELJANSKI, “Overview: BLRs as Inducers of In Vivo Leucocyte and Platelet Genesis.” Deutsche Zeitschrift für Onkologie, 24, 2, 1992, pp. 41-46.
Active: Europe - Japan - United States
Pending: Canada (CA) App. No. 2667149 - India (IN) App No. 3253/DELNP/2009 - China (CN) App No. 201510083122.6
Composition Per Unit: Ribonucleic extract of Escherichia coli K-12* 20 mg
*Source: Biological Cultures